1. Concurrent chemoradiotherapy with additional chemotherapy for nasopharyngeal carcinoma: A pooled analysis of propensity score‐matching studies
- Author
-
Xiaokai Mo, Lu Zhang, Jingjing You, Zhuozhi Chen, Bin Zhang, Luyan Chen, Zhe Jin, Qiuying Chen, Minmin Li, and Shuixing Zhang
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Humans ,Medicine ,Propensity Score ,Chemotherapy ,Nasopharyngeal Carcinoma ,business.industry ,Hazard ratio ,Induction chemotherapy ,Nasopharyngeal Neoplasms ,Chemoradiotherapy ,Induction Chemotherapy ,medicine.disease ,Confidence interval ,Concurrent chemoradiotherapy ,030104 developmental biology ,Otorhinolaryngology ,Nasopharyngeal carcinoma ,030220 oncology & carcinogenesis ,Meta-analysis ,Propensity score matching ,business - Abstract
Objective To determine the benefits of adding induction chemotherapy (IC) and adjuvant chemotherapy (AC) to concurrent chemoradiotherapy (CCRT) for nasopharyngeal carcinoma (NPC) based on propensity score-matching (PSM) studies. Methods Eligible PSM studies were searched in the PubMed, Web of Science, and Embase databases from inception to September 1, 2020. The primary endpoints included overall survival (OS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS). Results A total of 14 trials consisting of 4086 participants were included. Significant benefits were observed between IC + CCRT and CCRT for OS (hazard ratio [HR], 0.76; 95% confidence interval [CI]: 0.64-0.91) and DMFS (HR, 0.77; 95% CI: 0.64-0.94) with the exception of LRFS (HR, 1.14; 95% CI: 0.90-1.43). However, CCRT + AC did not achieve significant improvements. Conclusions IC with CCRT yields significant survival benefits in terms of OS and DMFS, whereas CCRT with AC fails to achieve any additional benefit in all endpoints.
- Published
- 2021